An overview of the current advances in the treatment of inflammatory diseases using mesenchymal stromal cell secretome.
- Resource Type
- Academic Journal
- Authors
- Joshi JM; Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India.; Muttigi MS; Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India.; Upadhya R; Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India.; Seetharam RN; Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India.
- Source
- Publisher: Informa Healthcare Country of Publication: England NLM ID: 8800150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2513 (Electronic) Linking ISSN: 08923973 NLM ISO Abbreviation: Immunopharmacol Immunotoxicol Subsets: MEDLINE
- Subject
- Language
- English
The growing interest in mesenchymal stromal cell (MSC) therapy has been leading to the utilization of its therapeutic properties in a variety of inflammatory diseases. The clinical translation of the related research from bench to bedside is cumbersome due to some obvious limitations of cell therapy. It is evident from the literature that the MSC secretome components mediate their wide range of functions. Cell-free therapy using MSC secretome is being considered as an emerging and promising area of biotherapeutics. The secretome mainly consists of bioactive factors, free nucleic acids, and extracellular vesicles. Constituents of the secretome are greatly influenced by the cell's microenvironment. The broad array of immunomodulatory properties of MSCs are now being employed to target inflammatory diseases. This review focuses on the emerging MSC secretome therapies for various inflammatory diseases. The mechanism of action of the various anti-inflammatory factors is discussed. The potential of MSC secretome as a viable anti-inflammatory therapy is deliberated.